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AbstrACt
Objectives Machado-Joseph disease (MJD) is the most 
common spinocerebellar ataxia worldwide. Prevalence is 
highest in affected remote Aboriginal communities of the 
Top End of Australia. Aboriginal families with MJD from 
Groote Eylandt believe ‘staying strong on the inside and 
outside’ works best to keep them walking and moving 
around, in accordance with six key domains that form 
the ‘Staying Strong’ Framework. The aim of this current 
study was to review the literature to: (1) map the range 
of interventions/strategies that have been explored to 
promote walking and moving around (functional mobility) 
for individuals with MJD and; (2) align these interventions 
to the ‘Staying Strong’ Framework described by Aboriginal 
families with MJD.
Design Scoping review.
Data sources Searches were conducted in July 2018 
in MEDLINE, EMBASE, CINAHL, PsychINFO and Cochrane 
Databases.
Eligibility criteria for selecting studies Peer-reviewed 
studies that (1) included adolescents/adults with MJD, (2) 
explored the effects of any intervention on mobility and 
(3) included a measure of mobility, function and/or ataxia 
were included in the review.
results Thirty studies were included. Few studies 
involved participants with MJD alone (12/30). Most studies 
explored interventions that aligned with two ‘Staying 
Strong’ Framework domains, ‘exercising your body’ (n=13) 
and ‘searching for good medicine’ (n=17). Few studies 
aligned with the domains having ‘something important to 
do’ (n=2) or ‘keeping yourself happy’ (n=2). No studies 
aligned with the domains ‘going country’ or ‘families 
helping each other’.
Conclusions Evidence for interventions to promote 
mobility that align with the ‘Staying Strong’ Framework 
were focused on staying strong on the outside (physically) 
with little reflection on staying strong on the inside 
(emotionally, mentally and spiritually). Findings suggest 
future research is required to investigate the benefits of 
lifestyle activity programmes that address both physical 
and psychosocial well-being for families with MJD.
IntrODuCtIOn
Machado-Joseph disease (MJD), or spinocere-
bellar ataxia type 3, is an autosomal-dominant 
neurodegenerative disease. Individuals with 
MJD experience progressive cerebellar ataxia 
and decline in mobility caused by premature 
cell death in the cerebellum and brainstem.1 
Average life expectancy is 20 years from 
onset of symptoms, with most individuals 
wheelchair users within 10 years of symptoms 
emerging.2 MJD is the most common spinoc-
erebellar ataxia (SCA) worldwide3 and is most 
prevalent in remote Aboriginal communities 
in the Top End of Australia. For example, 
prevalenace estimates for the Groote Eylandt 
Archipelago in Australia are ~743/100 000, 
compared with ~39/100 000 for the Azores 
Archipelago in Portugal, where MJD is also 
common.4–7
strengths and limitations of this study
 ► This is the first review to map interventions trialled 
for individuals with Machado-Joseph disease (MJD) 
to enhance walking and moving around and to align 
findings with the ‘Staying Strong’ Framework.
 ► Studies typically focussed on interventions that 
promote ‘staying strong on the outside’ (physically), 
with few targetting ‘staying strong on the inside’ 
(emotionally, mentally and spiritually).
 ► This study is limited by a shortage of high-quality 
research that includes individuals specifically with 
MJD.
 ► This review highlights opportunities for investigating 
the benefit of lifestyle activity programmes that ad-
dress both physical and psychosocial well-being for 
families with MJD.
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Table 1 ‘Staying Strong’ Framework
Domains Definition
Exercising 
your body
 ► Having an active lifestyle and keeping your body moving every day keeps you physically strong (ie, going 
country, walking, hunting, fishing swimming, dancing, doing housework and yard work, riding a bike, 
walking on a treadmill).
 ► Exercising your body helps you cope with the worries and sadness that come with MJD.
Something 
important to 
do
 ► Finding something meaningful to do pushes you to keep your body moving and keep physically strong.
 ► Having something important to do helps you feel you are contributing to your family and community, sets 
an example for others and builds self-esteem and happiness.
Keeping 
yourself happy
 ► Finding ways to stay happy and positive, and drawing on family and support services when required, helps 
you keep persevering in life despite having MJD.
 ► It helps you to keep doing the things you need to do to stay physically strong.
 ► Feeling low and unhappy can make you feel physically weak.
Searching for 
good medicine
 ► Searching for good medicine or food from the natural environment, or useful clinical medicines, is important 
for staying physically and emotionally strong.
 ► It is important to find good medicines that help you to manage other illnesses that negatively impact living 
with MJD (colds, flus, infections and pain).
 ► For Aboriginal people of Groote Eylandt, finding traditional medicines in the bush or beach is important for 
staying active and keeping physically and emotionally strong.
Going country  ► Going country means getting out and about, to places meaningful to the individual, to do things that matter, 
with people that matter, to keep yourself both physically and emotionally strong.
 ► For Aboriginal families of Groote Eylandt, going country involves getting out of the home, visiting their 
lands, at the bush or beach, often to go hunting or fishing with family.
Families 
helping each 
other
 ► Family support is important for having opportunities to keep physically strong and for physical assistance 
as the disease progresses.
 ► Support from families offers important emotional support, keeping you strong inside.
 ► Family extends to local and trusted service providers.
MJD, Machado-Joseph disease.
Many trials are underway to find a cure for a range of 
SCAs.8 9 Other research efforts have focused on physio-
therapeutic interventions to address impairments and 
activity limitations resulting from a range of hereditary 
ataxias (HAs).10–13 These interventions have been shown 
to enhance mobility and potentially delay symptom 
progression.14 For people with MJD, current recom-
mended physiotherapeutic interventions are based on 
findings from studies on other SCAs.13 15–17 A focus on 
MJD is required, given the differences in pathophysiology 
and neurochemistry between SCA types,9 and to under-
stand what interventions have been previously explored 
and where gaps lie. This information will provide future 
direction for targeted interventions for people with MJD 
to maximise their functional mobility.
Interventions designed to promote mobility for Aborig-
inal families with MJD from the Top End of Australia, 
whose culture and lifestyle are uniquely different to those 
with MJD in other parts of the world, have not been inves-
tigated.18 Importantly, these interventions are unlikely to 
be effective if they do not incorporate Indigenous views 
and concepts of physical activity and lifestyle in line with 
cultural and traditional practices.18–20
Aboriginal families with MJD from the Groote Eylandt 
Archipelago have experienced the impact of MJD on their 
families for generations.18 In a recent study,21 these fami-
lies shared their perspectives on what is important and 
what works best to keep walking and moving around.18 
Participants emphasised the importance of ‘staying strong 
on the inside and outside’ (physically, mentally, emotion-
ally and spiritually) through ‘exercising your body’, 
‘keeping yourself happy’, ‘going country’, ‘searching for 
good medicine’, ‘families helping each other’ and having 
‘something important to do’.18 These domains formed 
the ‘Staying Strong’ Framework to keep walking and 
moving around; a framework driven by community and 
culturally founded needs (table 1).18 This review set out 
to explore: (1) What interventions/strategies have been 
explored to promote walking and moving around for 
people with MJD (2); How the findings of these explo-
rations align with the perspectives of families with MJD 
from Groote Eylandt, according to the domains of the 
‘Staying Strong’ Framework.18
MEthODs AnD AnAlysIs
A scoping review was conducted following the five-step 
approach recommended by Arksey and O’Malley and 
further developed by Levac et al.22 23 A scoping review was 
chosen to allow a broad range of topics across a range 
of study types and designs to be explored, to identify the 
nature and extent of research evidence available.24 The 
Preferred Reporting Items for Systematic reviews and 
Meta-Analyses (PRISMA) extension for Scoping Reviews 
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Table 2 Search terms (MEDLINE)
Concept Search terms Limits
What
(interventions)
program* or promot* or interven* or strateg* or approach* or train* or rehab* or princip* or 
therap* or support* or motivat*
Nil
Works best
(promote, enhance)
benefi* or improv* or positiv* or significan* or maint* Nil
People with MJD
(initially broadened 
search to HAs to ensure 
all studies that may have 
included participants with 
MJD could be screened)
cerebellar ataxia/ or exp spinocerebellar ataxias/ or spinocerebellar degenerations/ 
or friedreich ataxia/ or olivopontocerebellar atrophies/ or ‘spinocerebellar ataxia*’ or 
‘machado joseph disease’ or ‘friedreich’s ataxia’ or ‘inherited olivopontocerebellar 
atrophy’ or ‘cerebello-olivary atrophy’ or ‘spinocerebellar degeneration’ or ‘genetic 
degenerative ataxia’ or ‘cerebellar ataxia’ or ‘hereditary ataxia’ or ‘genetic ataxia’ 
or ‘inherited ataxia’ or ‘dentatorubral pallidoluysian atrophy’ or ‘trinucleotide repeat 
dis*’ or ‘inherited neurodegenerative dis*’ or ‘degenerative ataxia’ or ‘hereditary 
neurodegenerative ataxia*’ or ‘autosomal dominant hereditary ataxia*’ or ‘autosomal 
recessive hereditary ataxia*’
Nil
Walking and moving 
around
(functional mobility)
exp Movement/ or exp Human Activities/ or exp Locomotion/ or Physical Mobility/ or 
Motor Activity/ or Stair Climbing/ or walk* or mobil* or function* or move* or moving or 
activit* or step* or stand* or transfer*
Nil
HAs, hereditary ataxias; MJD, Machado-Joseph disease.
Checklist was followed.25 This review was not registered 
with PROSPERO as scoping reviews are not currently 
accepted.
relevant studies
A comprehensive search of peer-reviewed published liter-
ature was conducted for studies published from 1990 
when genetic confirmation of MJD became possible,26 27 
until August 2018. The search was repeated prior to publi-
cation to identify studies published up to July 2019. 
Using MEDLINE, EMBASE, CINAHL, PsychINFO and 
Cochrane Databases, a combination of medical subject 
headings terms and keywords with truncations were used 
(table 2). The search was initially broad to include all 
HAs, to ensure inclusion of studies with participants with 
multiple aetiologies including MJD would be identified. 
Studies were chosen if they (1) included human partic-
ipants with genetically confirmed MJD either exclusively 
or within the study sample, (2) included adolescents and/
or adults, (3) included at least one measure of mobility, 
function or ataxia and (4) explored the influence of any 
intervention/strategy on mobility and/or function using 
objective measures or from the perspective of the partic-
ipant. In studies that did not disclose the types of SCA of 
included participants, authors were contacted to confirm 
inclusion or exclusion on this basis.
study selection and quality assessement
Database searches were conducted by one reviewer (JJC) 
and verified by a second reviewer (JQ). Both reviewers (JJC 
and JQ) independently screened titles and abstracts and 
reviewed full-text articles. Additional studies screened for 
inclusion were identified by handsearching reference lists 
of included studies, literature reviews that met the eligi-
bility criteria and through citations tracked using Google 
Scholar.1 8 9 11 12 14 28–31 The PRISMA flow diagram outlines 
the results of the search (figure 1).32 The second search 
found no new studies that met the inclusion criteria.
Methodological quality assessment of included studies, 
not typically required of scoping reviews, was employed 
to identify gaps in the literature and quality of the studies 
available.33 Two reviewers (JJC and MS) assessed meth-
odological quality of included studies using the Mixed 
Method Appraisal Tool (MMAT)34 and classified them 
according to the National Health and Medical Research 
Council (NHMRC) evidence hierarchy.35 The MMAT was 
selected as this single tool allowed quality appraisal of 
the range of study designs relevant to this review (qual-
itative, randomised controlled (RCTs), non-RCTs and 
quantitative descriptive studies). Joanna Briggs Institute 
(JBI) Levels of Evidence for Meaningfulness36 was used to 
grade level of evidence for the qualitative study37 and the 
expert opinion excerpt.1 Disagreements were resolved by 
consensus or referred to a third reviewer (RNB).
Data extraction, collation and analysis
To facilitate analysis and reporting, data were extracted 
using NVivo V.1238 following a data extraction guide. 
Data extracted included study characteristics, partic-
ipant characteristics, intervention characteristics, 
outcome measures and study outcomes. Data gathered 
were charted into tables.22 Measures of blood chemistry, 
neuroimaging or measures of upper limb function were 
not extracted unless included in composite or functional 
outcome measures, such as the Spinocerebellar Ataxia 
Functional Index (SCAFI).
All studies found were collated and then mapped 
according to the domains they aligned to in the ‘Staying 
Strong’ Framework (JJC). Studies that aligned to more 
than one domain were mapped under the domain to 
which they most strongly aligned (table 3). A descriptive 
approach was used to analyse the data collected.39 To 
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Figure 1 Flow diagram of study selection.
provide an overview, key points that highlight each study’s 
alignment with the different domains were compiled in a 
separate table (online supplementary table 1). Meta-anal-
ysis was not possible due to heterogeneity of outcome 
measures and interventions in the included studies.
Patient and pubic involvement
There was no patient or public involvement in this study.
rEsults
A total of 30 studies met the eligibility criteria and 
included quantitative (experimental (n=27); observa-
tional (n=1)) and qualitative (n=1) designs. One expert 
opinion excerpt (n=1) that was eligible and included was 
extracted from a literature review that otherwise did not 
meet the eligibility criteria. Twelve different countries 
were represented (Brazil (n=6), Germany (n=4), China 
(n=3), Japan (n=3), Taiwan (n=3), USA (n=3), India 
(n=2), Italy (n=2), Spain (n=2), Korea, the Netherlands 
and Scandinavia. Characteristics of the included studies 
are outlined in table 3.
study population
Of the 30 studies, 12 studies included MJD participants 
exclusively. The remaining 18 included participants with 
both MJD and other HAs. Mobility status was reported 
as ambulant in 21 studies, able to stand at a minimum 
in one study, while eight studies did not report mobility 
status. Study sample sizes ranged from eight to 295 partic-
ipants, with a total of 850 participants, 429 with MJD 
(50.5%). Age ranged from 15 to 76 (average across all 
studies=46.7 years).
Methodological quality
Seven quantitative studies were graded level II (RCTs) 
according to NHMRC levels of evidence.30 40–45 The 
remaining studies were graded III-1 (one study),46 
III-2 (three studies),47–49 III-3 (one study)50 and IV (16 
studies).51–66 The qualitative study was graded level 337 
and the expert opinion excerpt was graded level 51 in 
accordance with the JBI Levels of Evidence for Mean-
ingfulness.36 MMAT scores for methodological quality 
are provided in table 4. Quality scores ranged as follows 
*(n=1),48 **(n=6),41 43 51 54 58 64 ***(n=10)30 37 44 45 49 50 53 57 63 66 
and ****(n=12).40 42 46 47 52 55 56 59–62 65 The expert opinion 
excerpt was not scored.1
Outcome measures
Fifty-three different outcome measures were used to 
investigate interventions in this review. The SARA scale 
(14/30 studies) was the measure most commonly used. 
Outcome measures included measures at the impairment 
level (ataxia, disease severity and depression), measures 
at the activity level (function, mobility and balance) and 
measures of quality of life (QOL). No studies included 
measures at the participation level. Table 5 presents 
measures used, as well as outcomes that reached statistical 
significance.
Adverse events
Nine studies reported adverse events, all within phar-
macological studies. None were considered serious or 
life threatening.30 41 42 44 45 53 55 64 66 One study reported 
two-drop outs due to side effects, but details of the effects 
were not specified.64
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Table 4 Quality assessment of included studies using the Mixed Methods Appraisal Tool (MMAT)*
Author(s)†
Qualitative Quantitative RCT Quantitative non-random Quantitative descriptive
Total Score
Sources 
of data
Process 
for 
analysis Context
Researchers’ 
influence Randomisation Blinding
Outcome 
data
Dropout 
rate
Selection 
bias
Appropriate 
measurements
Compared 
groups Outcome data
Source 
strategy
Methods of 
analysis Context Reflexivity
Arpa et al  
2015
1 1 1 1 4/4 100
Assadi et al 
2007
0 1 1 1 3/4 75
Berntsson et al 
2017
0 1 1 1 3/4 75
Conte et al 
2017
1 1 1 1 4/4 100
de Oliveira  
et al 2015
1 1 1 1 4/4 100
de Oliveira  
et al 2018
1 0 1 0 2/4 50
Fonteyn et al 
2014
1 1 1 1 4/4 100
Giordano et al 
2013
0 1 0 1 2/4 50
Im et al 2017 1 1 1 1 4/4 100
Kaut et al 2014 1 1 1 1 4/4 100
Lei et al 2016 0 0 1 1 2/4 50
Leonardi et al 
2017
1 1 1 1 4/4 100
Liu et al 2005 0 1 1 1 3/4 75
Lo et al 2016 1 1 1 1 4/4 100
Monte et al 
2003
0 1 0 1 2/4 50
Sanz-Gallego 
et al 2014
1 1 1 0 3/4 75
Saute et al 
2014
1 1 1 1 4/4 100
Sawant and 
Gokhale 2015
0 1 1 1 3/4 75
Schulte et al 
2001
0 0 1 1 2/4 50
Shiga et al 
2002
0 1 1 1 3/4 75
Silva et al 2010 1 1 1 1 4/4 100
Tabbassum  
et al 2013
0 1 0 0 1/4 25
Takei et al 2004 0 1 1 1 3/4 75
Takei et al 2010 0 1 1 0 2/4 50
Tsai et al 2017 1 1 1 1 4/4 100
Wang et al 
2018
1 1 1 1 4/4 100
Wessel et al 
1997
0 1 1 1 3/4 75
Yang et al 2011 1 0 1 1 3/4 75
Zesiewicz et al 
2012
1 1 1 0 3/4 75
*A mixed-methods studies column was not included as no mixed-method studies were reviewed.
†D’Abreu et al 2010 was not scored (expert opinion excerpt).
1, criterion met; 0, criteria not met or unable to determine; RCT, randomised controlled trials.
study setting
Of the 27 experimental studies, 12 were conducted 
under supervision of a health professional in the outpa-
tient setting,40 46–49 52 56 59 60 62 63 two of which included 
an additional unsupervised home programme.52 63 In 
the remaining 15 studies, participants self-administered 
medications in their homes.30 42–45 49–51 53 54 64 65 The 
qualitative37 and longitudinal observational studies61 were 
conducted face to face in an outpatient Neurology clinic. 
Study setting was not relevant to the expert opinion 
excerpt.1 Assessments were carried out in the inpatient 
setting in three studies,41 55 57 outpatient setting for 12 
studies,30 42–45 49–51 53 54 64 65 both in two studies,41 57 while 
all follow-up took place in the outpatient setting.
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Interventions
A range of interventions have been explored, both phar-
macological and non-pharmacological. Overall, no phar-
macological interventions are currently recommended 
for use by indivudals with MJD. Non-pharmacological, 
exercise-based interventions, have had a positive impact 
on walking and moving around. Intervention types 
have been described under each of their corresponding 
domains in the ‘Staying Strong’ Framework (see table 3 
and online supplementary table 1). In relation to the 
International Classification of Functioning, Disability 
and Health framework,67 no interventions in this review 
targeted the participation level, but focussed predom-
inantly on the body functions and structures level and 
activity level.
Exercising your body
Thirteen studies discussed interventions which aligned 
with ‘exercising your body’.1 40 46–48 52 56–60 62 63 Exercise 
in general was reported to be beneficial in one study.1 
Specific interventions could be separated into three types 
of training: (1) walking training, (2) task specific training 
and (3) balance training. All studies related to ‘exercising 
your body’ reported significant findings, although only 
three of the 13 studies had a control group. Interven-
tions varied in type, duration and frequency. Interven-
tion sessions occurred on average for 51 min duration, 
2.7 times a week for 8 weeks. Dosages such as repetitions 
completed per session or intensity, in terms of effort per 
session, were not reported. Rest periods were reported in 
one study.47
Walking practice
Four studies investigated interventions that aligned to 
walking practice47 56 58 59 including training on a tread-
mill,56 58 over ground walking59 and walking with a wide 
base of support.47 All significantly improved either 
balance,47 58 ataxia56 59 and/or walking ability.47 56 59
Task-specific training
Two studies investigated task-specific training through 
ADL training alone52 or in combination with strength, 
balance, coordination, walking and cycling training.63 
ADL training alone significantly improved depression 
scores,52 but when combined with other task-specific 
training, balance and function also improved significantly 
after 12 weeks.63
Balance practice
Six studies explored interventions to challenge balance: 
balance training alone62 or in conjunction with ‘exer-
games’40; a wearable proprioceptive stabiliser60; core 
stability training48; stochastic vibration therapy46 and 
task-specific training.63 Significant improvements (both 
between and within groups) in balance,48 62 ataxia 
severity40 46 60 and walking46 60 were found. One study 
combined stem cell therapy with balance training (see 
below in ‘searching for good medicine’).57
searching for good medicine
Seventeen studies evaluated interventions that aligned 
with ‘searching for good medicine’. Fourteen different 
pharmacological interventions were explored, one in 
combination with balance training,57 as well as one 
non-pharmacological intervention (transcutaneous 
magnetic stimulation (TMS)). No studies evaluated tradi-
tional medicine or complementary medicine use.68 One 
study (expert opinion) recommended medications to 
minimise the sequalae of impairments as a result of MJD 
(ie, levodopa for dystonia, pain relief for pain).1 While 
some therapies demonstrated potential to reduce ataxia 
(valproic acid,41 lithium carbonate,42 varenicline)45 and 
improve function (lithium carbonate,42 TMS),49 efficacy 
had not been demonstrated. None of the interventions 
were recommended for use by individuals with MJD9 
(table 3).
Keeping yourself happy
Two studies aligned with ‘keeping yourself happy’.37 61 
Depression was found to have a significant negative impact 
on functional status and QOL, independent of ataxia, 
with suicidal ideation more common in MJD than in 
SCA1, SCA2 or SCA6.61 Participants living with ataxia 
shared the devastating impact of the disease on their 
social life, mood, parental roles, ADLs and employment, 
but recommended living in the present and taking 1 day 
at a time.37 Exercise was reported to help individuals with 
MJD cope and gain a sense of control over their disease.1 
However, only one study explored individualised interven-
tions designed to promote both physical and psychosocial 
well-being.52 Nine studies included measures of QOL or 
depression to evaluate their intervention42 43 45 52–54 58 64 66 
but only two studies53 54 demonstrated significant improve-
ments in those measures (table 5).53 54 The remainder 
reported either non-significant findings or did not report 
significance levels.
something important to do
Two studies aligned with having ‘something important 
to do’. Support from employers was important to main-
tain work roles.37 Loss of meaningful employment, lack 
of support from employers or changes to roles as a parent 
or provider had a negative impact on mood and iden-
tity.37 Only one study evaluated an intervention tailored 
to the goals/needs of the participant.52 Depression scores 
improved, but measures of function and QOL failed to 
reach significance.52 No other included studies explored 
goal orientated or task-specific training or training based 
on individual goals/priorities/interests.
Going country
No studies aligned with ‘going country’. All studies 
were conducted either in a hospital or research facility 
with the exception of two studies that included an unsu-
pervised home programme.52 63 No studies were found 
that explored ‘going country’, community participa-
tion, community engagement, vocational rehabilitation, 
outdoor mobility, sport and/or recreation in relation to 
mobility for individuals with MJD.
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Families helping each other
No studies aligned with ‘families helping each other’. No 
studies considered the influence of family support, inter-
ventions or rehabilitation with family, or the role of fami-
lies in supporting mobility and function for individuals 
with MJD.
DIsCussIOn
The purpose of this review was to map the range of 
interventions/strategies trialled for people with MJD to 
enhance walking and moving around and to align those 
interventions with the ‘Staying Strong’ Framework devel-
oped by individuals and families with MJD from the 
Groote Eylandt Archipeligo. Studies were typically of low 
quality and focused on what is largely staying strong on 
the outside: ‘exercising your body’ (walking training, 
balance training or task-specific training) and ‘searching 
for good medicine’ (various oral medicines, inject-
able medicines and non-pharmacological medicines). 
Few studies explored the impact on mobility of having 
‘something important to do’ (ie, goal orientated, or task 
specific training based on individual goals/priorities/
interests) or strategies for ‘keeping yourself happy’. No 
studies in this review considered the impact on mobility 
of ‘going country’ (community participation, outdoor 
mobility, sport/recreation) or ‘families helping each 
other’ (the impact or relationship of family support on 
functional mobility). This review thereby highlights an 
opportunity for meaningful, individualised, person-cen-
tred interventions to promote physical and psychosocial 
function, consistent with the views of families with MJD in 
Australia,18 and those living with ataxia in other parts of 
the world.69 70
Exercising your body
Overall, exercise or physical activity interventions were 
found to have positive effects on mobility for individ-
uals with MJD and to be generally safe, inexpensive and 
in current use. The most effective interventions and 
the optimal dosage could not be determined, due to 
heterogeneity of outcome measures and study designs. 
However, studies that engaged participants in at least 
50 min training, at least 2–3 times each week, for approxi-
mately 4 weeks, demonstrated improvement. This finding 
is consistent with ataxia research more broadly, that has 
shown higher intensity rehabilitation to be more effective 
(60 min, 2 days per week) than less intensive training.11 
Interestingly, no studies evaluated incidental physical 
activity or participants’ level of activity outside of the 
intervention, unlike studies in other progressive condi-
tions including Huntington’s disease (HD), multiple 
sclerosis and Parkinson’s disease (PD) literature.71 72 
Programmes and interventions that promote participa-
tion and an active lifestyle have well known benefits on 
mobility and well-being for individuals living with neuro-
logical disorders.73 Yet the amount of exercise suggested 
to bring benefit for people with MJD and other ataxias11 
suggests that lifestyle-orientated programmes that extend 
well beyond a 4-week intervention are required.74
searching for good medicine
Consistent with perspectives of families with MJD from 
the Groote Eylandt Archipelago,18 this review highlights 
the continued search for good medicine for individuals 
with MJD. The impact of traditional medicines or nutri-
tional supplements on functional mobility for those with 
MJD has not been studied as it has in HD and PD.75 76 
Furthermore, none of the many medications that were 
evaluated are currently indicated for MJD with most 
studies assessing drug safety with small samples. Notwith-
standing, in this review, individuals with MJD were better 
represented in pharmacological studies than in studies 
on physiotherapeutic interventions. While large sample 
size recruitment is an inevitable challenge in rare disease 
research,16 sample homogeneity within studies will be 
important moving forward to generate strong clinical 
recommendations for those with MJD.9 Consistent with 
other ataxias, current recommendations for pharmaco-
logical management for those with MJD relate largely 
to managing the sequalae of disease, such as spasticity, 
sleeping difficulties and incontinence.1 9
Going country
In this study and across all SCAs, research to explore 
community-based interventions in the context of an indi-
vidual’s environment or lifestyle is lacking, despite known 
benefits of engagement in sport, recreation and leisure 
activities for those with disabilities.77 Dance and participa-
tion in sport are some activities that have been evaluated 
for those with other neurodegenerative conditions.78 79 
While going country may be culturally and contextually 
specific to Aboriginal families with MJD in the Top End 
of Australia, individuals with ataxia in other parts of the 
world share similar views, relevant to their own context.80 
Participation in outdoor sports, self-developed exercises, 
team sports or community-based exercise classes, while 
beneficial physically, have also been found to promote 
self-esteem and well-being.70 Outdoor activities have 
helped individuals with ataxia manage depression and 
focus on living life to the fullest.70 Individuals with MJD 
generally remain ambulant up to 10 years following onset 
of symptoms,4 leaving opportunities for engagement in 
sport and recreational activities outside of a facility and 
in the community. Impairment focused intervention 
programmes restricted to indoor clinical facilities may 
overlook functional benefits that could be gained through 
participation in interventions that are fun, enjoyable and 
meaningful to the person.70 81 Research to evaluate the 
benefits of such interventions on mobility is warranted, 
for those with MJD and HAs more broadly.
something important to do and keeping yourself happy
Disappointingly, having ‘something important to do’ and 
‘keeping yourself happy’ were discussed minimally in the 
literature. The impact of depression on QOL for people 
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with SCAs is alarming, particularly the significantly higher 
rates of suicidal ideation for those with MJD.61 While a 
number of studies in this review included measures of 
depression and QOL,42 43 45 52–54 58 64 66 interventions tested 
appeared to have little impact on either. The sensitivity 
of the measures used over the generally short interven-
tion period should be taken into consideration.82 On 
the other hand, this may highlight a need for more indi-
vidualised interventions that target both physical and 
psychosocial well-being more effectively. The importance 
of self-selected meaningful exercise has been echoed by 
individuals with other degenerative ataxias, finding self-
chosen activities that offer physical challenge and person-
ally meaningful rewards, provide a sense of achievement, 
satisfaction and motivation to carry on.70 While evalua-
tion of the efficacy of individualised interventions does 
present challenges,83 programmes such as ParkFIT for PD 
in the Netherlands84 85 and Engage-HD for people with 
HD in the UK71 have provided examples on how these 
challenges can be overcome.73
Families helping each other
It is perhaps surprising, considering MJD is an auto-
somal-dominant disease, that no studies discussed the 
inclusion of family members as study participants. The 
devastating impact families face with autosomal-dominant 
neurodegenerative diseases is well known.86–88 While family 
support, peer socialisation and support through physical 
activity is a facilitator for engagement in physical activity for 
people with neurodegenerative diseases,89 no studies in this 
review discussed these factors. Furthermore, no studies eval-
uated group-based interventions, although the involvement 
of peers or family members in physiotherapeutic interven-
tions can enhance motivation, social support and long-term 
participation in physical activity.90 There is no doubt that 
the role of families is worthy of further investigation.
Outcome measures
Consensus and validation of outcome measures for indi-
viduals with MJD is required, with consideration given 
to outcomes in terms of all the domains of the ‘Staying 
Strong’ Framework. Reaching agreement on recom-
mended outcome measures for people with MJD will be 
an important step for future clinical trials and develop-
ment of clinical guidelines for management of MJD over 
the course of the disease. Guidelines for people with 
inherited ataxias have been developed,91 as have guide-
lines for those with Friedreich’s ataxia,92 but the partic-
ular issues individuals and their families with MJD face 
require specific attention.
limitations
There were few studies that contained participants exclu-
sively with MJD, so it is difficult to draw conclusions 
specifically for people with MJD. However, the findings 
do highlight the dearth of evidence relating to walking 
and moving around for individuals with MJD. While there 
may be interventions trialled that have had a positive 
impact on functional mobility, they are yet to be evaluated. 
Additional studies may exist that focus on domains such 
as having ‘something important to do’, ‘keeping yourself 
happy’ and ‘families helping each other’, but these may 
not have been found on initial searches if they did not 
include a functional mobility-related keyword. However, 
search strategies in this review were used to identify inter-
ventions that promoted functional mobility through 
staying strong both on the inside and outside.
COnClusIOn
This scoping review mapped studies that investigated the 
range of interventions to keep people with MJD walking 
and moving around. Findings were compared with ‘what 
works best’ according to families with MJD from the 
Groote Eylandt Archipelago. Interventions which aligned 
with their ‘Staying Strong’ Framework18 were largely 
limited to staying strong on the outside (physically), with 
little reflection on staying strong on the inside (emotion-
ally, mentally and spiritually). The findings of this review 
suggest future research is required to investigate the 
benefit of lifestyle activity programmes that address both 
physical and psychosocial well-being for families with 
MJD. Detailed reporting on the physical and psychoso-
cial aspects of these interventions, and on the develop-
ment and delivery of these programmes will help guide 
programme implementation for health service providers 
and clinicians working alongside families with MJD. The 
‘Staying Strong’ Framework presented community and 
culturally founded needs that provided a way to identify 
significant gaps in the literature and highlight where 
those needs have not been met. Considerably more effort 
in culturally informed research is required.
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